Frankfurt - Delayed Quote EUR

TME Pharma N.V. (0N6A.F)

0.0666

-0.0009

(-1.33%)

As of 3:29:01 PM GMT+1. Market Open.

TME Pharma Announces Successful Completion of €2.6 Million Public Offer With Strong Shareholder Support

BERLIN, December 23, 2024--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241222406657/en/

Business Wire last month

ALTME.PA

TMBSZ.PA
TME Pharma Provides Results of Fourth Exercise of Warrants Z

BERLIN, December 20, 2024--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), provides results of the fourth exercise of Warrants Z and an update on the outstanding number of ordinary shares and Warrants Z as of the settlement date taking place today. The exercise of 432 Warrants Z has resulted in the issuance of 540 new shares for gros

Business Wire last month

ALTME.PA

TMBSZ.PA
TME Pharma Announces the Launch of Fully Guaranteed Public Offer for €2.6 Million Open Only to Shareholders to Enable Completion of Strategic Transactions by June 2025

BERLIN, December 12, 2024--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211593283/en/

Business Wire last month

ALTME.PA

TMBSZ.PA
CORRECTING and REPLACING: TME Pharma Announces Corporate Strategy Update and Upcoming €2.6 Million Guaranteed Financing With Intention to Launch Public Offer Open Only to Shareholders to Enable Completion of Transactions ...

BERLIN, December 04, 2024--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204635944/en/

Business Wire last month

ALTME.PA

TMBSZ.PA
TME Pharma Announces Corporate Strategy Update and Upcoming €2.6 Million Guaranteed Financing With Intention to Launch Public Offer Open Only to Shareholders to Enable Completion of Transactions Around NOX-A12 and NOX-E36 by June 2025

BERLIN, December 04, 2024--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203688140/en/

Business Wire last month

ALTME.PA

TMBSZ.PA
TME Pharma Announces Poster Presentation by U.S. National Cancer Institute on CXCL12 Inhibition by NOX-A12 in Glioblastoma at 2024 SNO Annual Meeting

BERLIN, November 23, 2024--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces the presentation of a poster featuring NOX-A12 data from preclinical studies performed at the U.S. National Cancer Institute (NCI) at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting, taking place in Houston, Texas, USA, November 21-24, 2024.

Business Wire 2 months ago

ALTME.PA

TMBSZ.PA
TME Pharma Awarded €2.4 Million German Federal Grant to Support NOX-A12 Phase 2 Trial in Brain Cancer

BERLIN, October 31, 2024--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241031648935/en/

Business Wire 2 months ago

ALTME.PA

TMBSZ.PA
TME Pharma Reports H1 2024 Financial Results and Provides Business and Clinical Update

BERLIN, October 18, 2024--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces its financial results for the six months ending June 30, 2024, and provides business and clinical highlights and an outlook for the rest of the year.

Business Wire 3 months ago

ALTME.PA

TMBSZ.PA
TME Pharma Announces Appointment of Alexandra Glucksmann to Supervisory Board

BERLIN, September 30, 2024--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the nomination of Dr. Alexandra Glucksmann to the Supervisory Board was approved at the extraordinary general meeting of shareholders (EGM), which took place on September 30, 2024, at 01:30 p.m. CEST. Shareholders representing a total of

Business Wire 3 months ago

ALTME.PA

TMBSZ.PA
TME Pharma Provides Results of Third Exercise of Warrants Z

BERLIN, September 27, 2024--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), provides results of the third exercise of Warrants Z and an update on the outstanding number of ordinary shares and Warrants Z as of the settlement date taking place today. The exercise of 1,552 Warrants Z has resulted in the issuance of 1,940 new shares for

Business Wire 3 months ago

ALTME.PA

TMBSZ.PA
TME Pharma Announces Acceptance of the NCI’S Abstract on NOX-A12 in Glioblastoma for Presentation at the SNO 2024 Annual Meeting

BERLIN, September 19, 2024--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces that an abstract highlighting NOX-A12 data from preclinical studies performed by the U.S. National Cancer Institute (NCI) has been selected for poster presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting, taking place in Houston,

Business Wire 4 months ago

ALTME.PA

TMBSZ.PA
TME Pharma Announces Oral Presentation at ESMO Congress 2024 With Updated Results From NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma

BERLIN, September 16, 2024--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced an oral presentation by Dr. Frank A. Giordano, lead investigator of the NOX-A12 GLORIA Phase 1/2 trial in first-line brain cancer (glioblastoma), taking place on Sunday, September 15, 2024, at the European Society for Medical Oncology (ESMO) Congres

Business Wire 4 months ago

ALTME.PA

TMBSZ.PA
TME Pharma Announces Convocation of an Extraordinary General Meeting of Shareholders

BERLIN, August 27, 2024--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that an extraordinary general meeting of shareholders (the EGM) of the company is convened at 01.30 p.m. CEST on September 30, 2024, at the offices of Freshfields Bruckhaus Deringer LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, the Netherlands.

Business Wire 4 months ago

ALTME.PA

TMBSZ.PA
TME Pharma Provides Update on Resources Allocated to the Liquidity Contract With Invest Securities

BERLIN, August 12, 2024--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that it has increased the resources allocated to the liquidity contract entrusted to Invest Securities by the transfer of 349 treasury shares following the closure of an account as part of an internal optimization process.

Business Wire 5 months ago

ALTME.PA

TMBSZ.PA
TME Pharma N.V.: Half-Yearly Report on the Liquidity Contract With Invest Securities

BERLIN, July 31, 2024--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that pursuant to the liquidity contract entrusted to Invest Securities by TME Pharma N.V. the assets outlined below appeared on the liquidity account as of June 30, 2024.

Business Wire 5 months ago

ALTME.PA

TMBSZ.PA
TME Pharma Announces Strategic Plan to Externalize and Monetize Second Clinical Stage Asset NOX-E36

BERLIN, July 22, 2024--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces its plan to externalize and monetize the company's second clinical stage asset NOX-E36 – an L-stereoisomer RNA aptamer inhibiting the CCL2 chemokine. This decision leverages the compound’s potential, as shown by clinical and preclinical data, to safely a

Business Wire 6 months ago

ALTME.PA

TMBSZ.PA
TME Pharma Announces Oral Presentation of NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma at ESMO Congress 2024

BERLIN, July 17, 2024--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that an abstract featuring results from the NOX-A12 GLORIA Phase 1/2 trial in first-line brain cancer (glioblastoma) has been selected for presentation at the European Society for Medical Oncology (ESMO) Congress taking place in Barcelona, Spain, S

Business Wire 6 months ago

ALTME.PA

TMBSZ.PA
TME Pharma N.V.: CEO Message H1 2024

BERLIN, July 09, 2024--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), released today a message from Aram Mangasarian, CEO of TME Pharma, to its shareholders.

Business Wire 6 months ago

ALTME.PA

TMBSZ.PA
TME Pharma Provides Results of Second Exercise of Warrants Z

BERLIN, June 28, 2024--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), provides results of the second exercise of Warrants Z and an update on the outstanding number of ordinary shares and Warrants Z as of the settlement date taking place today. The exercise of 513,472 Warrants Z has resulted in the issuance of 641,840 new shares for

Business Wire 6 months ago

ALTME.PA

TMBSZ.PA
TME Pharma Announces Appointment of Lee Schalop to Supervisory Board and Approval of All Resolutions Submitted to the 2024 Annual General Meeting of Shareholders

BERLIN, Germany, June 27, 2024--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the approval of all resolutions submitted to its 2024 annual general meeting of shareholders (AGM), which took place on June 27, 2024, at 01:30 p.m. CEST. Shareholders representing a total of 2.21% of the total issued and outstanding share

Business Wire 6 months ago

ALTME.PA

TMBSZ.PA

Performance Overview

Return	0N6A.F	CAC 40
YTD	-3.06%	+8.27%
1-Year	-67.67%	+3.73%
3-Year	-99.67%	+13.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TME Pharma N.V. (0N6A.F)

TME Pharma Announces Successful Completion of €2.6 Million Public Offer With Strong Shareholder Support

TME Pharma Provides Results of Fourth Exercise of Warrants Z

TME Pharma Announces the Launch of Fully Guaranteed Public Offer for €2.6 Million Open Only to Shareholders to Enable Completion of Strategic Transactions by June 2025

CORRECTING and REPLACING: TME Pharma Announces Corporate Strategy Update and Upcoming €2.6 Million Guaranteed Financing With Intention to Launch Public Offer Open Only to Shareholders to Enable Completion of Transactions ...

TME Pharma Announces Corporate Strategy Update and Upcoming €2.6 Million Guaranteed Financing With Intention to Launch Public Offer Open Only to Shareholders to Enable Completion of Transactions Around NOX-A12 and NOX-E36 by June 2025

TME Pharma Announces Poster Presentation by U.S. National Cancer Institute on CXCL12 Inhibition by NOX-A12 in Glioblastoma at 2024 SNO Annual Meeting

TME Pharma Awarded €2.4 Million German Federal Grant to Support NOX-A12 Phase 2 Trial in Brain Cancer

TME Pharma Reports H1 2024 Financial Results and Provides Business and Clinical Update

TME Pharma Announces Appointment of Alexandra Glucksmann to Supervisory Board

TME Pharma Provides Results of Third Exercise of Warrants Z

TME Pharma Announces Acceptance of the NCI’S Abstract on NOX-A12 in Glioblastoma for Presentation at the SNO 2024 Annual Meeting

TME Pharma Announces Oral Presentation at ESMO Congress 2024 With Updated Results From NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma

TME Pharma Announces Convocation of an Extraordinary General Meeting of Shareholders

TME Pharma Provides Update on Resources Allocated to the Liquidity Contract With Invest Securities

TME Pharma N.V.: Half-Yearly Report on the Liquidity Contract With Invest Securities

TME Pharma Announces Strategic Plan to Externalize and Monetize Second Clinical Stage Asset NOX-E36

TME Pharma Announces Oral Presentation of NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma at ESMO Congress 2024

TME Pharma N.V.: CEO Message H1 2024

TME Pharma Provides Results of Second Exercise of Warrants Z

TME Pharma Announces Appointment of Lee Schalop to Supervisory Board and Approval of All Resolutions Submitted to the 2024 Annual General Meeting of Shareholders

Performance Overview